EMA Authorised: Lutathera (lutetium (177Lu) oxodotreotide) — Novartis Europharm Limited

View source ↗

Summary

Lutetium-177 Lu oxodotreotide (Lutathera) has been authorised by EMA for neuroendocrine tumors, designated as an orphan medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Status: Authorised. Therapeutic area: Neuroendocrine Tumors. MAH: Novartis Europharm Limited. Decision date: 13/08/2026. Orphan medicine